A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06422884
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05817240
- Locations
- 🇦🇺
Research Site, Adelaide, South Australia, Australia
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05199584
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04968574
- Locations
- 🇲🇽
Research Site, Puebla, Mexico
🇰🇷Research Site (Bundang District), Seongnam, Korea, Republic of
🇰🇷Research Site (Namdong District), Incheon, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath